Vivos Therapeutics exchanges USD 2.86 million Streeterville note principal for up to 11,445,080 shares

• Vivos Therapeutics agreed to exchange $2.86 million of secured promissory note principal for up to 11,445,080 common shares.
• Twelve exchange agreements dated Aug. 31, 2026 partitioned the balance into 12 secured promissory notes later surrendered for stock.
• Exchange price averaged $0.25 per share, set at or above Nasdaq’s minimum price under Listing Rule 5635(d).
• The transactions reduce the outstanding principal balance of the Streeterville secured promissory note by $2.86 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041616), on September 08, 2026, and is solely responsible for the information contained therein.